Keywords: Myocardium, CEST & MT, preclinical, hypertrophic cardiomyopathy
Motivation: Hypertrophic cardiomyopathy is the most common inherited cardiovascular disorder and the most common cause of sudden cardiac death in people under 35. Early biochemical changes are currently undetectable, leading to diagnosis only in late disease stages.
Goal(s): Is it possible to detect early biochemical changes in transgenic models of HCM using CEST-MRI?
Approach: Using a recently developed method for ungated, preclinical cardiac CEST-MRI, two transgenic models of early HCM, heterozygous littermates, and WT mice were imaged and multiple CEST contrasts were analyzed.
Results: Despite small sample sizes, differences in both creatine and amide CEST contrasts are becoming apparent between MyHC mutants and controls.
Impact: Early biochemical changes associated with hypertrophic cardiomyopathy are currently undetectable with conventional imaging. CEST-MRI and associated CEST contrasts allow for these changes to be detected and studied.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords